AllianceBernstein’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-162,790
Closed -$553K 3183
2018
Q3
$553K Sell
162,790
-4,520
-3% -$16.3K ﹤0.01% 2576
2018
Q2
$629K Buy
167,310
+13,960
+9% +$68K ﹤0.01% 2526
2018
Q1
$627K Buy
153,350
+15,200
+11% +$70.8K ﹤0.01% 2449
2017
Q4
$642K Buy
138,150
+510
+0.4% +$2.81K ﹤0.01% 2464
2017
Q3
$977K Sell
137,640
-54,010
-28% -$388K ﹤0.01% 2293
2017
Q2
$1.39M Buy
191,650
+54,010
+39% +$337K ﹤0.01% 2111
2017
Q1
$848K Sell
137,640
-11,700
-8% -$64.1K ﹤0.01% 2322
2016
Q4
$875K Hold
149,340
﹤0.01% 2327
2016
Q3
$793K Sell
149,340
-11,700
-7% -$63.1K ﹤0.01% 2331
2016
Q2
$1.07M Hold
161,040
﹤0.01% 2180
2016
Q1
$752K Sell
161,040
-15,500
-9% -$61.9K ﹤0.01% 2254
2015
Q4
$892K Hold
176,540
﹤0.01% 2197
2015
Q3
$621K Sell
176,540
-160
-0.1% -$1.07K ﹤0.01% 2404
2015
Q2
$1.76M Sell
176,700
-1,600
-0.9% -$17.2K ﹤0.01% 1903
2015
Q1
$2.27M Buy
178,300
+1,600
+0.9% +$20.6K ﹤0.01% 1632
2014
Q4
$2.5M Sell
176,700
-5,600
-3% -$86.8K ﹤0.01% 1581
2014
Q3
$2.51M Hold
182,300
﹤0.01% 1544
2014
Q2
$2.8M Buy
182,300
+30,700
+20% +$435K ﹤0.01% 1520
2014
Q1
$2.58M Sell
151,600
-239
-0.2% -$3.61K ﹤0.01% 1514
2013
Q4
$1.97M Buy
151,839
+2,037
+1% +$24.3K ﹤0.01% 1716
2013
Q3
$1.51M Buy
149,802
+2
+0% +$18 ﹤0.01% 1882
2013
Q2
$1.12M Buy
+149,800
New +$1.17M ﹤0.01% 2012

AllianceBernstein's KERX Position: Q4 2018 in Review

AllianceBernstein sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 162,790 shares — an estimated $553K sold.

AllianceBernstein first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $2.8M in Q2 2014. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • AllianceBernstein reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • AllianceBernstein sold 162,790 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $553K.
  • AllianceBernstein first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
  • AllianceBernstein's Keryx Biopharmaceuticals Inc position peaked at $2.8M in Q2 2014.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on AllianceBernstein's 13F filing for Q4 2018, filed 13 Feb 2019.